Javascript must be enabled to continue!
Development and validation of spectroscopic simultaneous equation method for simultaneous estimation of Azelnidipine and Valsartan in synthetic mixture
View through CrossRef
A simple, specific, accurate and precise spectrophotometric method was developed and validated for simultaneous estimation of Azelnidipine and Valsartan in Synthetic Mixture. The wavelength of estimation for Azelnidipine was 240.00 nm and for Valsartan was 250.00 nm. Beer’s law is obeyed in the concentration range of 2-10μg/ml and 16-80μg/ml and correlation coefficient of 0.9999 and 0.9993 for Azelnidipine and Valsartan respectively. The % recovery for Azelnidipine and Valsartan were found to be 101.2 % - 101.9 % and 101.8 - 101.9 % respectively. Intraday precision of Azelnidipine and Valsartan were found to be 0.06 – 0.24 and 0.08 – 0.27 % RSD and Interday precision were found to be 0.14 – 0.33 and 0.11 – 0.37 % RSD respectively. The proposed method was also evaluated by the Assay of Synthetic mixture containing Azelnidipine and Valsartan. The % Assay was found to be 100.50 ± 0.002 for Azelnidipine and 100.87 ± 0.001 for Valsartan. Validation of proposed methods was carried out according to ICH Q2R1Guidelines. The proposed methods were found accurate and reproducible for routine analysis of both the drugs in synthetic mixture.
Title: Development and validation of spectroscopic simultaneous equation method for simultaneous estimation of Azelnidipine and Valsartan in synthetic mixture
Description:
A simple, specific, accurate and precise spectrophotometric method was developed and validated for simultaneous estimation of Azelnidipine and Valsartan in Synthetic Mixture.
The wavelength of estimation for Azelnidipine was 240.
00 nm and for Valsartan was 250.
00 nm.
Beer’s law is obeyed in the concentration range of 2-10μg/ml and 16-80μg/ml and correlation coefficient of 0.
9999 and 0.
9993 for Azelnidipine and Valsartan respectively.
The % recovery for Azelnidipine and Valsartan were found to be 101.
2 % - 101.
9 % and 101.
8 - 101.
9 % respectively.
Intraday precision of Azelnidipine and Valsartan were found to be 0.
06 – 0.
24 and 0.
08 – 0.
27 % RSD and Interday precision were found to be 0.
14 – 0.
33 and 0.
11 – 0.
37 % RSD respectively.
The proposed method was also evaluated by the Assay of Synthetic mixture containing Azelnidipine and Valsartan.
The % Assay was found to be 100.
50 ± 0.
002 for Azelnidipine and 100.
87 ± 0.
001 for Valsartan.
Validation of proposed methods was carried out according to ICH Q2R1Guidelines.
The proposed methods were found accurate and reproducible for routine analysis of both the drugs in synthetic mixture.
Related Results
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Abstract
Background
In the VICTORIA trial (n=5050) the reduction in the primary composite endpoint of cardiovascular death (CVD)...
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with...
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
Pengaruh Valsartan Terhadap Fibrosis Ginjal pada Obstruksi Ureter
AbstrakPendahuluan : Obstruksi ureter merupakan kondisi yang dapat terjadi pada setiap usia dengan levelbervariasi dengan efek terburuk berupa gagal ginjal permanen. Terdapat berba...
Designing, Critical Characterization, and Analytical RP-HPLC Method Development for Simultaneous Quantifications of Azelnidipine and Telmisartan Cocrystal
Designing, Critical Characterization, and Analytical RP-HPLC Method Development for Simultaneous Quantifications of Azelnidipine and Telmisartan Cocrystal
Introduction:
Azelnidipine and telmisartan are hypertensive medicines that belong to the BCS class II category and have low solubility and high permeability.
Cr...
The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice
The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice
Background
To investigate whether Valsartan plays a role in vascular endothelial cells in plaque and hs-CRP with ApoE knockout mice, thus improving plaque stabili...
Stability Assessment through HPTLC for Concurrent Assessment of Azelnidipine and Telmisartan in Mass and Integrated Tablet Drug Formulation
Stability Assessment through HPTLC for Concurrent Assessment of Azelnidipine and Telmisartan in Mass and Integrated Tablet Drug Formulation
This study aims to estimate the stability assessment through HPTLC for the concurrent assessment of (±)3-(1-diphenylmethylazetidin-3-yl)5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(...
Simultaneous spectrophotometric determination of valsartan and hydrochlorothiazide by H-point standard addition method and partial least squares regression
Simultaneous spectrophotometric determination of valsartan and hydrochlorothiazide by H-point standard addition method and partial least squares regression
Simultaneous spectrophotometric determination of valsartan and hydrochlorothiazide by H-point standard addition method and partial least squares regression
Simultaneous det...
DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION
DEVELOPMENT OF ASSAY METHOD AND FORCED DEGRADATION STUDY OF VALSARTAN AND SACUBITRIL BY RP-HPLC IN TABLET FORMULATION
Objective: A stability-indicating high performance liquid chromatographic (HPLC) method was developed and validated for the estimation of combined tablet formulation of valsartan a...

